skip to Main Content

The EASL Liver Cancer Summit 2023 will take place 20-22 April in Estoril, Portugal.

Venue: Estoril Congress Center.

More details about the summit will be available in due time.

Organising Committee

Prof. Nathalie Ganne-Carrié
Paris, France

Nathalie Ganne-Carrié is Professor in Hepatology, head of the liver unit of the Hôpitaux Universitaires Paris Seine Saint-Denis, France (Avicenne, Bobigny) in which more than 50% of the activity is dedicated to primary liver tumor, and a clinical researcher at INSERM U1138.

Click to read more

She has gained her medical degree in Hepato-Gastroenterology in 1992 and in Oncology in 2013 from the University of Paris 6, and completed a PhD in University of Lyon 1 in 2004 and a Higher Degree for Research (HDR) at the University of Paris 13 in 2010. Since 2019, she is the general secretary of AFEF, the French Society of Hepatology, and also member of the board of SNFGE, the French Society of Hepato-Gastroenterology.

Professor Ganne-Carrié’s research interests focus on the complications of cirrhosis in particular hepatocellular carcinoma using local ressources and French national cohorts  (CIRRAL, CirVir, HEPATHER) in several aspects including early detection, therapeutic innovations, and prognosis. She is the Scientific Coordinator of the French National cohort CIRRAL, which is a prospective follow-up of 652 patients with compensated alcohol-related cirrhosis in 22 centres across France and Belgium. This cohort allowed the achievement of several publications since 2018 in major international journals including Journal of Hepatology.

She has published more than 200 papers and book chapters, and is an ad hoc reviewer for Journal of Hepatology and numerous other scientific journals including Lancet Gastroenterology and Hepatology, Hepatology, and Liver International.

Prof. Mathias Heikenwälder
Heidelberg, Germany

Prof. Heikenwälder and his group investigate the molecular and cellular mechanisms that lead to chronic inflammation, tissue damage, cancer and metastasis. In tight collaboration with clinics he is working on new models and therapy approaches. Prof. Heikenwälder studied microbiology in Vienna.

Click to read more

After a two-year-research trip at the Max-Delbrück-Zentrum for medicine in Berlin graduated 1999 with highest honors. He started his doctoral thesis at the institute of neuropathology in Zurich and successfully graduated 2004 on the field of prion diseases. After his habilitation at the medical faculty oft he Universitätsspital Zürich he received 2007 a Max-Cloëtta-Professorship and started his work as a group leader with the research focus on “inflammation and cancer”. In the year 2010he became junior professor at the TUM as well as group leader at the institute for virology at the Helmholtz Zentrum in Munich, and became a Peter Hans Hofschneider Professor. Since 2015 Prof. Heikenwälder is heading the department „Chronic inflammation and cancer” at the German Cancer Research Centre in Heidelberg.

Major Commendations

  • Highly cited scientist (2020; Clarivate Cross fields)
  • Highly cited scientist (2020; Clarivate Cross fields)
  • Highly cited scientist (2019; Clarivate Cross fields)
  • Prize of the Swiss Foundation against liver cancer
  • ERC POC 2018
  • ERC Consolidator Grant (2016)
  • Walther und Christine Ritzenhain-Preis (2012)
  • ERC Starting Grant (2010)
  • Hans-Peter Hofschneider-Preis (2010)
  • Götz-Preis, vergeben an der Universität Zürich, Schweiz (2009)
  • Max-Cloëtta Professorship (2007)
  • EMPIRIS Award (2006)
  • Creutzfeld-Preis (2004)

Prof. Bruno Sangro 
Pamplona, Spain

Prof. Bruno Sangro is Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra in Pamplona, Spain. He currently serves as Past President of the International Liver Cancer Association.

Click to read more

He is also Professor of Internal Medicine and leads an active research group in the Spanish Network for Biomedical Research on Hepatic and Digestive Diseases (CIBEREHD), focused on therapeutic innovation in the field of liver cancer.

Back To Top